Bruker Corporation Acquires Canopy Biosciences, LLC

Canopy Biosciences Acquires Zellkraftwerk GmbH

April 29, 2019

Biotechnology

Canopy Biosciences acquired Leipzig-based Zellkraftwerk GmbH, adding Zellkraftwerk’s ChipCytometry multiplex cytometry instruments and related services to Canopy’s multi-omics portfolio. Concurrently, Ampersand Capital Partners made a strategic growth investment in Canopy to support geographic expansion and product/service scale-up across the US, Europe and Asia.

Canopy Biosciences Acquires Core Diagnostics

December 4, 2019

Biotechnology

Canopy Biosciences, a St. Louis-based multi-omic services company backed by Ampersand Capital Partners, has acquired Core Diagnostics, a California CLIA-certified biomarker analysis laboratory. The acquisition gives Canopy CLIA-certified laboratory capabilities to offer its multi-omic immune profiling services to clinical as well as preclinical and translational customers.

Bruker Corporation Acquires PhenomeX Inc.

August 17, 2023

Biotechnology

Bruker Corporation agreed to acquire PhenomeX Inc. in an all-cash transaction valued at roughly $108 million (purchase price $1.00 per share). PhenomeX — formed from the combination of Berkeley Lights and IsoPlexis and provider of single-cell biology instruments, software and reagents — will be folded into a Bruker subsidiary, marking Bruker’s entry into single-cell biology research tools and complementing its spatial biology offerings.

Bruker Corporation Acquires biocrates life sciences ag

June 3, 2025

Biotechnology

Bruker Corporation has acquired biocrates life sciences ag, an Innsbruck, Austria-based leader in mass-spectrometry-based quantitative metabolomics. The deal adds biocrates' metabolomics kits, assays, software and contract research services to Bruker's multiomics strategy, expanding Bruker's MS-based metabolomics and integrated multiomics capabilities. Financial terms were not disclosed.

Bruker Corporation Acquires NanoString Technologies Business

May 6, 2024

Medical Devices

Bruker Corporation has acquired substantially all assets of NanoString Technologies, Inc. through a court-supervised Chapter 11 asset sale for approximately $392.6 million in cash plus assumption of certain liabilities. The deal, announced April 2024 and closed in late April/early May 2024, brings NanoString's spatial biology and gene-expression product lines into Bruker to preserve customer access, product development, and jobs while expanding Bruker's life‑science instrumentation capabilities.

Bruker Corporation Acquires Neurescence Inc.

November 12, 2022

Medical Devices

Bruker Corporation has signed a definitive agreement to acquire 100% of Neurescence Inc., a Toronto-based developer of ultralight fiber‑bundle Multiscopes (Chromatone) for multi-region optical functional neuroimaging. The acquisition strengthens Bruker's preclinical neuroscience imaging capabilities and complements its existing Ultima multiphoton solutions and recently acquired Inscopix products; financial terms were not disclosed.